A Randomized, Double-blinded, Placebo-controlled, Parallel Group, Phase 2a Study to Assess the Activity, Safety, and Tolerability of SAR445399 in Adult Participants With Non-Cystic Fibrosis Bronchiectasis (NCFB)
Latest Information Update: 03 May 2026
At a glance
- Drugs SAR 445399 (Primary)
- Indications Bronchiectasis
- Focus Therapeutic Use
- Sponsors Sanofi
Most Recent Events
- 03 May 2026 New trial record